Literature DB >> 8869332

Plasminogen activators in oesophageal carcinoma.

D F Hewin1, P B Savage, D Alderson, M N Vipond.   

Abstract

The expression of components of the plasminogen activator system was investigated in patients with oesophageal carcinoma. Tumour and normal mucosa were obtained from resected oesophageal carcinomas and antigens were measured by enzyme-linked immunosorbent assay. Median levels of urokinase plasminogen activator (uPA) and the uPA receptor were higher in carcinoma than in matched normal mucosa (squamous cell carcinoma: uPA 4.05 versus 0.66 ng antigen per mg protein, uPA receptor 1.95 versus 0.50 ng/mg, n = 10, P < 0.05; adenocarcinoma: uPA 2.16 versus 0.61 ng/mg, uPA receptor 2.01 versus 0.49 ng/mg, n = 8, P < 0.05). Tissue plasminogen activator (tPA) level was lower than control values in squamous cell carcinoma but not in adenocarcinoma (1.97 versus 4.70 ng/mg, P < 0.05). There was no difference in plasminogen activator inhibitor (PAI) 1 level between carcinoma and normal mucosa. The PAI-2 level was lower than that in normals in adenocarcinoma only (6.0 versus 64.77 ng/mg, P < 0.05). These data support the hypothesis that membrane-bound uPA has a role in the breakdown of extracellular matrix in invasive oesophageal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8869332     DOI: 10.1002/bjs.1800830838

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.

Authors:  D Morrissey; J O'Connell; D Lynch; G C O'Sullivan; F Shanahan; J K Collins
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

3.  Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.

Authors:  H Shiomi; Y Eguchi; T Tani; M Kodama; T Hattori
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

4.  Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines.

Authors:  Benjamin A Onwuegbusi; Jonathan R E Rees; Pierre Lao-Sirieix; Rebecca C Fitzgerald
Journal:  PLoS One       Date:  2007-01-31       Impact factor: 3.240

5.  Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma.

Authors:  Baoqing Tian; Xiaojia Chen; Huihua Zhang; Xiaoyan Li; Jiakang Wang; Wei Han; Li-Yi Zhang; Li Fu; Yan Li; Changjun Nie; Ying Zhao; Xuan Tan; Hailong Wang; Xin-Yuan Guan; An Hong
Journal:  Oncotarget       Date:  2017-06-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.